drugset / Trial / NCT04595981

Chemo-embolization for Head and Neck Cancer

NCT04595981

NaSingle-groupOpen-labelTreatment

Summary

The study will evaluate whether adjuvant chemo-embolization increases progression free and/or overall survival relative to standard of care radiation and chemo- and/or immunotherapy in cisplatin-ineligible head and neck cancer patients with an acceptable morbidity rate.

Timeline

Start
2027-05
Primary completion
2029-05
Completion
2030-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 150 mg Other
Subject Cisplatin Other / unclassified 150 mg/m2 Other
Subject Cisplatin Other / unclassified 300 mg Other